Gilead’s CAR T-Cell Therapy Administered to Just Five Patients in Two Months

More than 200 people are on waiting lists for the $373,000 treatment as hospitals try to work around problems with insurers. 

By | December 18, 2017

WIKIMEDIA, NEPHRONGilead Sciences’s blood cancer therapy has been administered to just five patients in the two months since its approval, according to a report published last Thursday (December 14) in Bloomberg. Waiting lists for Yescarta—a CAR T-cell treatment for large B-cell lymphomas—have reportedly surpassed 200 people, with some very sick patients dying before receiving the therapy.

Originally developed by Kite Pharma—a California-based startup that was bought by Gilead for nearly $12 billion in cash earlier this year—Yescarta is just the second CAR T-cell therapy to be approved in the U.S. Doctors at the 15 cancer hospitals authorized to administer the novel therapy cite problems in obtaining payment for the $373,000 treatment from insurers, including Medicare and Medicaid. “There’s no billing codes for this,” Michael Bishop, director of the cellular therapy program at the University of Chicago Medicine hospital, tells Bloomberg. “It’s been difficult, to be blunt.”

See “FDA Approves Second CAR T-Cell Therapy

While some hospitals are holding off purchasing the treatment until insurance is guaranteed, others are exploring alternatives. Doctors at MD Anderson Cancer Center—which has a waiting list of more than 100—are allowing patients to sign waivers that say the patients themselves will foot the bill for the treatment if insurers refuse. Stanford University, meanwhile, is admitting patients whatever their insurance situation. “My institution is bearing the risk because it’s the right thing to do,” Stanford physician David Miklos tells Bloomberg. “But it’s a huge risk and it’s keeping me awake at night.”

At the time of its October approval, Yescarta was hailed as a “milestone in the development of a whole new scientific paradigm for the treatment of serious diseases” in a statement by US Food and Drug Administration Commissioner Scott Gottlieb. David Maloney, medical director of cellular immunotherapy at Fred Hutchinson Cancer Research Center, predicted on NBC that “there will likely be thousands of lives saved in the next few years because of it.”

See “The CAR T-Cell Race

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  2. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  3. DOE-Sponsored Oak Ridge National Laboratory to Cut 100 More Jobs
  4. Neurons Use Virus-Like Proteins to Transmit Information
AAAS